Glasgow, Scotland, 17 November 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, announces today that it has successfully completed a topical formulation feasibility study with its lead antibacterial MGB-BP-3.
The pre-clinical study assessed two preliminary topical formulations of MGB-BP-3 in a skin infection model against a methicillin resistant Staphylococcus aureus (MRSA). The study showed that both formulations of MGB-BP-3 were successful in killing approximately 60% of the MRSA present. These very promising findings pave the way for MGB Biopharma to begin a full topical formulation development programme for MGB-BP-3 with the goal of commercialising this novel antibacterial for a range of important skin infections.
Dr Miroslav Ravic, CEO of MGB Biopharma, said: “We are very pleased to be able to report that encouraging efficacy data has been obtained using MedPharm’s infected skin model against S. aureus, using non-optimised simple formulations and we are now looking at a number of options that will allow us to further optimise and develop this promising program.”
MGB-BP-3 is a truly novel compound, based on minor groove binder (MGB) technology developed by the scientists from the University of Strathclyde. It represents a new class of drugs with a new mechanism of action that could transform the treatment of common, and potentially fatal, infectious diseases. In addition to medicines against Gram-positive pathogens, the MGB-based anti-infective platform has the potential to deliver drugs against multi-resistant Gram-negative pathogens, viruses, fungi and parasites.
For further information, please contact:
MGB Biopharma Citigate Dewe Rogerson
Miroslav Ravic, Chief Executive Officer David Dible
Dr Dawn Firmin, Head of Project Management +44 (0) 20 7282 2949
+44 (0) 208 946 0120
About MGB Biopharma
MGB Biopharma, is a clinical stage company developing a truly novel class of anti-infectives. Its lead candidate, MGB-BP-3, is an antibacterial that is active against a broad range of important multi-resistant Gram-positive pathogens. The Company has developed an oral formulation of MGB-BP-3 for the treatment of Clostridium difficile, currently in Phase I. An intravenous formulation targeting the treatment of a range of systemic hospital acquired Gram-positive infections is in late-stage preclinical development, and a topical formulation for the treatment of serious skin infections has successfully completed a feasibility assessment.
MGB Biopharma has acquired the proprietary minor groove binder (MGB) platform, developed at the University of Strathclyde, Glasgow, with exclusive worldwide licensing rights for all anti-infective fields. This platform provides an opportunity to develop various compounds with a completely new mode of action which are distinct from the antimicrobial drugs used in clinical practice today. Consequently many MGB-based drugs offer significant advantages over existing anti-infectives, such as MGB-BP-3, which exhibits high efficacy against many multi-drug susceptible and resistant Gram-positive pathogens. To-date no resistance to MGB compounds has been observed.
The Company intends to work with partners to fully capitalise on the multiple value creating opportunities offered by its broad and innovative anti-infectives platform.
The Company, founded in 2010 and headquartered in Glasgow, Scotland, is backed by Scottish investors including Archangel Investors, Barwell, TRI Cap and the Scottish Investment Bank, Scottish Enterprise.
For more information please visit www.mgb-biopharma.com.